<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/25/bio-rad-laboratories-nysebio-reaches-new-12-month-high-at-369-61.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-25T11:58:42+00:00"/>
    <meta property="og:title" content="Bio-Rad Laboratories (NYSE:BIO) Reaches New 12-Month High at $369.61"/>
    <meta property="og:description" content="Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) hit a new 52-week high on Monday . The company traded as high as $369.61 and last traded at $369.21, with a volume of 920 shares changing hands. The stock had previously closed at $362.18. Several research firms have issued reports on BIO. ValuEngine downgraded Bio-Rad Laboratories from a […]"/>
  </head>
  <body>
    <article>
      <h1>Bio-Rad Laboratories (NYSE:BIO) Reaches New 12-Month High at $369.61</h1>
      <address><time datetime="2019-11-25T11:58:42+00:00">25 Nov 2019, 11:58</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/bio-rad-laboratories-inc-logo.jpg"/>
      </figure>
      <p>Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) hit a new 52-week high on Monday . The company traded as high as $369.61 and last traded at $369.21, with a volume of 920 shares changing hands. The stock had previously closed at $362.18.</p>
      <p>Several research firms have issued reports on BIO. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=BIO">ValuEngine</a> downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. Barclays increased their price objective on Bio-Rad Laboratories from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. They noted that the move was a valuation call. Finally, Goldman Sachs Group upgraded Bio-Rad Laboratories from a “buy” rating to a “conviction-buy” rating and set a $400.00 price objective on the stock in a report on Tuesday, August 20th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Bio-Rad Laboratories has a consensus rating of “Buy” and an average price target of $378.75.</p>
      <p>The stock has a market cap of $10.78 billion, a P/E ratio of 63.18, a PEG ratio of 3.34 and a beta of 1.16. The company has a quick ratio of 3.36, a current ratio of 4.72 and a debt-to-equity ratio of 0.12. The business has a 50-day simple moving average of $345.27 and a 200-day simple moving average of $323.35.</p>
      <p>Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, October 31st. The medical research company reported $1.61 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.25. Bio-Rad Laboratories had a return on equity of 4.30% and a net margin of 16.14%. The company had revenue of $560.60 million during the quarter, compared to analysts’ expectations of $561.40 million. During the same period in the prior year, the business earned $0.91 earnings per share. Bio-Rad Laboratories’s revenue for the quarter was up 2.8% compared to the same quarter last year. On average, analysts predict that Bio-Rad Laboratories, Inc. will post 7.2 earnings per share for the current fiscal year.</p>
      <p>In related news, EVP John Hertia sold 838 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $328.29, for a total value of $275,107.02. Following the transaction, the executive vice president now owns 18,966 shares in the company, valued at $6,226,348.14. The transaction was disclosed in a document filed with the SEC, which is available through <a href="https://www.sec.gov/Archives/edgar/data/12208/000165225219000075/xslF345X03/edgar.xml">this hyperlink</a>. Also, VP James R. Stark sold 848 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $351.45, for a total value of $298,029.60. The disclosure for this sale can be found <a href="https://www.sec.gov/Archives/edgar/data/12208/000131540619000018/xslF345X03/edgar.xml">here</a>. Insiders sold 8,414 shares of company stock valued at $2,833,735 over the last 90 days. 27.84% of the stock is currently owned by corporate insiders.</p>
      <p>A number of institutional investors have recently bought and sold shares of BIO. Swiss National Bank boosted its holdings in Bio-Rad Laboratories by 2.1% during the second quarter. Swiss National Bank now owns 39,307 shares of the medical research company’s stock worth $12,287,000 after buying an additional 800 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Bio-Rad Laboratories by 1.2% during the 2nd quarter. BlackRock Inc. now owns 1,950,805 shares of the medical research company’s stock valued at $609,803,000 after purchasing an additional 22,263 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of Bio-Rad Laboratories by 162.5% during the 3rd quarter. Quadrant Capital Group LLC now owns 273 shares of the medical research company’s stock valued at $87,000 after purchasing an additional 169 shares in the last quarter. Commerce Bank lifted its holdings in shares of Bio-Rad Laboratories by 7.1% during the 2nd quarter. Commerce Bank now owns 873 shares of the medical research company’s stock valued at $273,000 after purchasing an additional 58 shares in the last quarter. Finally, CSat Investment Advisory L.P. bought a new position in shares of Bio-Rad Laboratories during the 2nd quarter valued at about $132,000. Institutional investors and hedge funds own 63.78% of the company’s stock.</p>
      <p><b>About Bio-Rad Laboratories</b> (<a href="https://www.marketbeat.com/stocks/NYSE/BIO/">NYSE:BIO</a>)</p>
      <p>Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.</p>
      <p>Read More: <a href="https://www.marketbeat.com/market-data/dogs-of-the-dow-stocks/">How the Dogs of the Dow Strategy Works</a></p>
    </article>
  </body>
</html>